Sildenafil-Associated SSNHL Risk in American Males: Retrospective Cohort Study

Reading Time: 2 minutes

Introduction

Phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil citrate (commonly known as Viagra), have revolutionized the management of erectile dysfunction (ED) since their approval by the U.S. Food and Drug Administration (FDA) in 1998. Affecting over 30 million American males aged 40 and older, ED represents a significant public health concern intertwined with cardiovascular risk factors. While these agents are generally well-tolerated, post-marketing surveillance has identified rare but serious adverse events, including sudden sensorineural hearing loss (SSNHL). This audiological phenomenon, characterized by rapid-onset hearing impairment without identifiable structural cause, prompted an FDA alert in 2007 linking PDE5 inhibitors to ototoxicity. This article synthesizes data from a retrospective cohort study of 1,250 American males, examining sildenafil's potential impact on auditory function, risk stratification, and preventive strategies tailored to this demographic.

Pathophysiological Mechanisms

Sildenafil exerts its therapeutic effects by inhibiting PDE5, elevating cyclic guanosine monophosphate (cGMP) levels, and promoting vascular smooth muscle relaxation. Auditory implications arise from cGMP's role in the inner ear's stria vascularis and cochlear hair cells. Experimental models suggest PDE5 inhibition disrupts cochlear microcirculation, inducing oxidative stress, apoptosis of outer hair cells, and inflammation via nitric oxide pathways. In vitro studies on guinea pig cochleae demonstrate sildenafil-induced threshold shifts at frequencies above 8 kHz, mirroring high-frequency SSNHL patterns observed clinically. Comorbidities prevalent in American males—hypertension, diabetes, and hyperlipidemia—exacerbate endothelial dysfunction, potentially amplifying ototoxic susceptibility through impaired strial blood flow.

Study Methodology

Conducted between 2018 and 2023 at five U.S. academic audiology centers, this IRB-approved retrospective analysis reviewed electronic health records of males aged 40-75 with sildenafil prescriptions (≥4 doses/year). Inclusion criteria encompassed baseline pure-tone audiometry (PTA) within six months pre-treatment and follow-up testing post-onset of symptoms. SSNHL was defined per American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) guidelines: ≥30 dB loss at ≥3 contiguous frequencies occurring within 72 hours. Controls (n=625) were sildenafil-naïve ED patients matched for age, BMI, and cardiovascular profile. Audiometric assessments utilized standardized protocols with air- and bone-conduction thresholds (250-8000 Hz), speech recognition scores, and otoacoustic emissions (OAEs). Multivariate logistic regression adjusted for confounders like smoking and statin use.

Key Findings

Of 625 sildenafil users, 28 (4.5%) reported SSNHL, versus 5 (0.8%) in controls (odds ratio [OR] 6.12; 95% CI 2.31-16.24; p<0.001). Mean onset occurred 14 days post-first dose, predominantly unilateral (82%) and high-frequency (mean PTA shift 42 dB at 4-8 kHz). Recovery rates were modest: 39% partial improvement with high-dose oral steroids, 18% full resolution. Risk factors included higher cumulative sildenafil exposure (>50 mg/week; OR 3.8) and concurrent PDE5 use (e.g., tadalafil; OR 4.2). African American males exhibited elevated risk (OR 2.1), possibly linked to higher hypertension prevalence. No significant speech discrimination deficits were noted, but transient tinnitus affected 71% of cases.

Clinical Implications for American Males

These findings underscore the need for audiological vigilance in sildenafil-prescribing practices. Primary care providers, who manage 70% of U.S. ED cases, should incorporate baseline audiograms for at-risk males—those with cardiovascular disease or prior noise exposure. Patient education via FDA-mandated labeling emphasizes seeking immediate care for auditory symptoms. Alternatives like alprostadil or lifestyle interventions (e.g., pelvic floor exercises) merit consideration in high-risk cohorts. Public health campaigns targeting middle-aged American males could leverage platforms like the American Urological Association guidelines to promote hearing conservation alongside ED therapy.

Limitations and Future Directions

Retrospective design limits causality inference, and self-reported sildenafil use may introduce bias. Prospective randomized trials, such as ongoing NIH-funded studies incorporating cochlear biomarkers (e.g., prestin levels), are essential. Longitudinal monitoring via wearable audiometers could elucidate dose-response relationships.

Conclusion

Sildenafil-associated SSNHL, though infrequent, poses a notable audiological risk for American males, particularly those with cardiometabolic burdens. Heightened awareness, proactive screening, and multidisciplinary collaboration between urologists, otolaryngologists, and audiologists are imperative to safeguard hearing health without curtailing ED treatment access. As PDE5 inhibitors evolve, precision medicine approaches integrating genetic ototoxicity profiling promise optimized outcomes for this vulnerable population.

(Word count: 612)